Conjunctival hemorrhagic events associated with imatinib mesylate

Franca Radaelli; Claudia Vener; Francesco Ripamonti; Alessandra Iurlo; Mariangela Colombi; Andrea Artoni; Gianluigi Reda; Giorgio Lambertenghi Deliliers

doi:10.1532/IJH97.E0741

Conjunctival hemorrhagic events associated with imatinib mesylate

Franca Radaelli, Claudia Vener, Francesco Ripamonti, Alessandra Iurlo, Mariangela Colombi, Andrea Artoni, Gianluigi Reda, Giorgio Lambertenghi Deliliers

Research output: Contribution to journal › Article › peer-review

Abstract

Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.

Original language	English
Pages (from-to)	390-393
Number of pages	4
Journal	International Journal of Hematology
Volume	86
Issue number	5
DOIs	https://doi.org/10.1532/IJH97.E0741
Publication status	Published - Dec 2007

Keywords

CML
Conjunctival hemorrhage
Imatinib
STI571

ASJC Scopus subject areas

Hematology

Access to Document

10.1532/IJH97.E0741

Fingerprint Dive into the research topics of 'Conjunctival hemorrhagic events associated with imatinib mesylate'. Together they form a unique fingerprint.

Cite this

Conjunctival hemorrhagic events associated with imatinib mesylate. / Radaelli, Franca; Vener, Claudia; Ripamonti, Francesco; Iurlo, Alessandra; Colombi, Mariangela; Artoni, Andrea ; Reda, Gianluigi; Deliliers, Giorgio Lambertenghi.

In: International Journal of Hematology, Vol. 86, No. 5, 12.2007, p. 390-393.

Research output: Contribution to journal › Article › peer-review

@article{20bf2ebe2a974ec3a30e97932cd66b8f,

title = "Conjunctival hemorrhagic events associated with imatinib mesylate",

abstract = "Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.",

keywords = "CML, Conjunctival hemorrhage, Imatinib, STI571",

author = "Franca Radaelli and Claudia Vener and Francesco Ripamonti and Alessandra Iurlo and Mariangela Colombi and Andrea Artoni and Gianluigi Reda and Deliliers, {Giorgio Lambertenghi}",

year = "2007",

month = dec,

doi = "10.1532/IJH97.E0741",

language = "English",

volume = "86",

pages = "390--393",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Conjunctival hemorrhagic events associated with imatinib mesylate

AU - Radaelli, Franca

AU - Vener, Claudia

AU - Ripamonti, Francesco

AU - Iurlo, Alessandra

AU - Colombi, Mariangela

AU - Artoni, Andrea

AU - Reda, Gianluigi

AU - Deliliers, Giorgio Lambertenghi

PY - 2007/12

Y1 - 2007/12

N2 - Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.

AB - Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.

KW - CML

KW - Conjunctival hemorrhage

KW - Imatinib

KW - STI571

UR - http://www.scopus.com/inward/record.url?scp=38349052256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349052256&partnerID=8YFLogxK

U2 - 10.1532/IJH97.E0741

DO - 10.1532/IJH97.E0741

M3 - Article

C2 - 18192104

AN - SCOPUS:38349052256

VL - 86

SP - 390

EP - 393

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -

Conjunctival hemorrhagic events associated with imatinib mesylate

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this